PubMed Health⌕ Search

Biomedical subjects

Michael Drexler

Publications and source records attributed to Michael Drexler.

2 recordsLinked to original sources

Both processing speed and semantic memory organization predict verbal fluency in schizophrenia.

We systematically examined the relationship of both lexical retrieval and semantic memory organization to categorical verbal fluency performance in 40 outpatient schizophrenic subjects and 16 healthy controls. Mean choice reaction time (RT) on a lexical decision task was used as a measure of lexical retrieval efficiency. The complexity of semantic memory organization was measured using a Pathfinder semantic network analysis (calculated as the number of inter-node links obtained from a similarity rating task). In the schizophrenia group only, RT and semantic network links were each significantly negatively correlated with fluency and, together, accounted for 23% of the variance in fluency. RT and links were not significantly correlated with one another. Findings were unrelated to age, sex, education, or medication dose. Controlling for IQ reduced but did not abolish the relationship between fluency and network links. We conclude that the restricted verbal output of schizophrenic subjects is related both to impaired lexical retrieval and to variation in semantic memory organization, which partly reflects general intelligence. The statistical independence of the retrieval speed and organizational factors suggests that individuals with schizophrenia differ in the underlying processes that contribute to their reduced verbal fluency.

Adult↗

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial treatment of proximal DVT with a fixed-dose, body weight-independent application of the LMWH Certoparin with a six month follow-up. In a prospective, multicentre, randomized, active-controlled study 1220 patients with objectively diagnosed proximal DVT were randomly assigned to subcutaneous 8000 U anti-factor Xa of Certoparin twice daily for 10 to 14 days or intravenous aPTT-adjusted UFH for 5 to 8 days. Both regimen were followed by oral anticoagulation for 6 months. The primary end point was the rate of symptomatic and objectively confirmed thromboembolic events within 6 months. The aim of the study was to demonstrate the non-inferiority of the Certoparin regimen as compared to UFH. The per-protocol analysis revealed 22 (3.8%) thromboembolic events in the Certoparin group and 24 (4.3%) in patients assigned to UFH within 6 months, thereby proving the non-inferiority (p<0.01), confirmed by intent-to-treat analysis (p<0.001). Major bleeding occurred in 6 and 7 patients started on Certoparin or UFH during the treatment period. Thromboembolic events were equally distributed in body weight categories with < 50, 50-80 and >80 kg as followed: 0, 3.6% and 4.1% of patients for the Certoparin group and 0, 4.6% and 4.2% of patients for the UFH group. The same was true for major bleeding complications with 0, 2.9% and 1.5% for Certoparin and 0, 3.5% and 4.2% for UFH. Overall mortality was 1.9% in the Certoparin group and 2.7% in the UFH group. Fixed-dose body weight-independent subcutaneous LMWH Certoparin is at least as efficacious and safe as intravenous aPTT-adjusted UFH for the initial treatment of acute proximal DVT. This effect is maintained during a 6-months follow-up of treatment with oral anticoagulation.

Aged↗